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INTRODUCTION

6
4a. In 2002-2003, I developed and modified several study instruments including telephone questionnaire, call logs, and other procedural forms. I have developed protocols for patient recruitment, random digit dialing, interviewer training and other interviewer procedures. I have designed a database for patient tracking and data entry and several reports to monitor study progress. 4b. I continue to be involved in project management of the Nashville Breast Health Study and have helped to train research coordinators to continue management. Following the conclusion of this training grant, I will continue to serve as a co-investigator for this on-going study. 4c. Recruitment for the Nashville Breast Health Study is on-going. At this time, the sample size is not sufficient for data analyses. Once data are ready, I will continue my involvement in manuscript preparation in my capacity as a co-investigator.
Task 5: Prepare a grant proposal for continuation. Months 28-34.
a. Develop and submit a grant proposal to expand the sample size of the nested casecontrol study to evaluate folate, global DNA methylation, and uracil misincorporation in lymphocytes in relation to breast cancer risk. 5 . As a result of the training provided by funding from this grant, I have submitted two grant proposals to the National Cancer Institute evaluating DNA methylation, one-carbon metabolism and colorectal adenoma risk. As the results of the folate and genetic information become available from the nested case-control study supported by this grant, additional grant proposals will be submitted. o Project management of the Nashville Breast Health Study; over 1800 participants have been recruited o Folate assays for the nested case-control study. Over 160 matched sets have been completed. o Genotype assays for the nested case-control study. 
KEY RESEARCH ACCOMPLISHMENTS
•
REPORTABLE
CONCLUSIONS
This study has made good progress and the laboratory assays will continue following the conclusion of this grant. Credit for any publications will be given to this DOD training grant. Results from the MTHFR and breast cancer risk manuscript indicate that MTHFR genotype alone is not associated with breast cancer risk. However, MTHFR genotype may affect the degree to which folate is protective in breast cancer risk. This is one of the first and largest studies to examine this association. It will be important to verify this relationship in the nested case-control study supported by this grant. The analysis of MTHFR genotype and breast cancer survival indicates that MTHFR genotype is a risk factor for death from breast cancer among women who have had chemotherapy and have late-stage disease. Future studies will be necessary to evaluate whether the type of chemotherapy received affects this association. Results from the MTR and MTRR and breast cancer risk manuscript do not support an important role of genetic variants in these enzymes in risk for breast cancer or a significant interaction with MTHFR variants or nutrient intake.
The development of breast cancer in participants in the Shanghai Women's Health Study has been lower than initially expected. As a result, it was not possible to finish all of Task 3 during the timeframe of this training grant. However, each of the specific tasks is in process and will be completed. Additional coursework, two grant proposals, and an additional publication were completed as a result of this training grant, although not part of the initial scope. I have become involved in the study design and management of two additional cancer epidemiology studies as a result of my experience with the Nashville Breast Health Study. This further expanded my ability to become an independent investigator and these studies were used to strengthen and supplement the grant application in Task 5.
Introduction
Folate is involved in DNA methylation, synthesis, and repair. Low intake of folate may increase risk for several cancers, including breast cancer (1, 2) . The enzyme methylenetetrahydrofolate reductase (MTHFR) irreversibly catalyzes 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the donor for the remethylation of homocysteine to methionine, the precursor for the universal methyl donor, S-adenosylmethionine (3, 4) . Folate that is not converted through this pathway can be used for purine synthesis or the conversion of uracil to thymine, which is used for DNA synthesis and repair (5) .
Two common polymorphisms in the MTHFR gene have been characterized (6, 7) . The 677C 3 T polymorphism codes for an alanine to valine substitution in the N-terminal catalytic domain and results in an allozyme with ϳ65% and ϳ30% of the wild-type homozygote activity for heterozygotes and homozygotes of the variant allele, respectively (6, 8) . The A3 C polymorphism at nucleotide 1298 codes for an alanine to glutamine substitution in the C-terminal regulatory domain (7) . Individuals homozygous for the 1298C allele have approximately the same enzyme activity as those heterozygous for the 677T allele (7, 8) .
The C677T polymorphism has been examined in relation to several cancers (2, 9) . In most studies of colorectal neoplasms, the MTHFR 677TT genotype has been associated with an overall reduction in risk, reduced risk among those with higher intakes of folate (10 -13), or increased risk among those with lower folate intakes (13) (14) (15) . MTHFR has not been as well studied in relation to breast cancer risk. Only three small studies have evaluated the association between MTHFR genotype and breast cancer (16 -18) . The results from these studies have been inconsistent. Only one study assessed both the C677T and A1298C polymorphisms and their possible joint effect with folate intake (18) . However, in that study, only 60 cases were included. We reported recently that folate intake was inversely associated with breast cancer risk in a large population-based, case-control study among Chinese women in Shanghai (19) . In an extension of these results, we investigated whether this association may be modified by MTHFR genotypes.
Materials and Methods
The Shanghai Breast Cancer Study is a population-based, casecontrol study conducted in urban Shanghai, China during 1996 -1998. This study was approved by the committees for the use of human subjects in all collaborating institutions. Detailed study methods have been published previously (20) . Subjects. All incident breast cancer cases newly diagnosed during the study period and meeting the eligibility criteria were identified through a rapid case-ascertainment system supple-mented by the Shanghai Cancer Registry and were approached for participation in the study. Eligibility criteria for the study were as follows: 25-64 years of age, resident of urban Shanghai, no previous history of any cancer, and alive at the time of interview. In all, 1602 eligible cases were identified, of whom 1459 (91.1%) completed in-person interviews. The median interval from cancer diagnosis to the in-person interview was 64 days. With the exception of a breast cancer diagnosis, controls had inclusion criteria identical to those of the cases and were frequency matched on age (5 years intervals) to the expected age distribution of the cases. In all, 1724 eligible controls were randomly selected from the Shanghai Resident Registry. Of these, 1556 (90.3%) completed in-person interviews. Data and Biological Sample Collection. All subjects completed an in-person interview that used a structured questionnaire and incorporated anthropometric measurements. Dietary intakes were assessed using a 76-item food frequency questionnaire (FFQ). In a recent validation study of the FFQ among 200 women, we found that the FFQ captured Ͼ86% of food intake in Shanghai (21) . Each subject was asked about the frequency that a specific food was eaten (daily, weekly, monthly, yearly, or never), followed by a question on the amount typically eaten. Dietary intakes of total folate and folate cofactors were derived from the FFQ by summing the product of the micronutrient content of each food item, usual portion eaten, and frequency of consumption. Because of the lack of folate data in the Chinese food composition database, an identical (82%) or equivalent (17%) item from the United States Department of Agriculture food composition database was used to determine micronutrient level (19) . To assess the comparability of the Chinese and United States Department of Agriculture food composition databases, we evaluated the correlation of three other watersoluble vitamins (vitamin C, riboflavin, and niacin) and found excellent correlation; all Pearson correlation coefficients were r Ն 0.91 or higher, providing ancillary support for the validity of derived folate data in this study. In a validation study of the FFQ among 200 women, the FFQ was administered twice in a year and Pearson correlation for folate was r ϭ 0.36. Blood samples were collected from 1193 (82%) cases and 1310 (84%) controls and used in this study for genotyping assays. Laboratory Methods. Genomic DNA was extracted from blood samples with the Puregene DNA isolation Kit (Gentra Systems, Minneapolis, MN) following the protocol of the manufacturer. Genotyping for the MTHFR C677T and A1298C polymorphisms were performed using PCR-RFLP methods reported by Frosst et al. (6) and Weisberg et al. (7) , with minor modifications. The primers for C677T analysis were 5Ј-TGAAGGAGAAGGTGTCTGCGGGA-3Ј (exonic) and 5Ј-AGGACGGTGCGGTGAGAGTG-3Ј (intronic). The primers for A1298C analysis were 5Ј-GGGAGGAGCTGACCAGTG-CAG-3Ј and 5Ј-GGGGTCAGGCCAGGGGCAG-3Ј. The PCR reactions were performed in a Biometra TGradient Thermocycler. Each 20 l of PCR mixture contained 10 ng DNA, 1ϫ PCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 9.0)], 1.5 mM MgCl 2 , 0.2 mM each of deoxynucleoside triphosphate, 0.5 mM of each primer, and 1 unit of TaqDNA polymerase. The reaction mixture was initially denatured at 94°C for 3 min. For C677T polymorphisms, PCR was performed in 30 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 45 s. For A1298C polymorphisms, PCR was performed in 35 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 45 s. The PCR was completed by a final extension cycle at 72°C for 7 min.
For C677T polymorphisms, each PCR product (10 l) was digested with 10 units of Hinf I at 37°C for 3 h. The DNA fragments were then separated using 3% agarose gel and detected by ethidium bromide staining. The C3 T substitution at nucleotide 667 creates a Hinf I digestion site. The PCR product (198 bp) with the T allele was digested to two fragments (175 bp and 23 bp), whereas the PCR product with wild-type C allele cannot be cut by Hinf I. For A1298C polymorphisms, each PCR product (10 l) was digested with 5 units of Fnu4H I at 37°C for 3 h, followed by 3% agarose gel electrophoresis and ethidium bromide staining. The A3 C substitution at nucleotide 1298 creates a Fnu4H I site. The PCR product (138 bp) with C allele was digested to two fragments (119 bp and 19 bp), whereas the PCR product with wild-type A allele cannot be cut by Fnu4H I. Quality-control samples were included in various batches of samples assayed for the polymorphisms. The consistency rate was 98.5% in 119 quality-control samples that were repeated in the genotyping assays with their identities unknown to laboratory staff. Excluding a few subjects for whom sufficient DNA was not available or for whom the genotyping assay failed, genotyping data were obtained from 1112 cases and 1160 controls for C677T and 1121 cases and 1208 controls for A1298C polymorphisms. Because few women in the study consumed alcohol, a factor that may increase folate requirements, and because the data on the folate content of vitamins were not available, all analyses involving folate or its cofactors were limited to the cases (92.0%) and controls (91.1%) who were known not to consume alcohol regularly and not to take vitamin supplements. Data Analysis. Odds ratios (ORs) were used to measure the association of breast cancer risk with MTHFR genotype. Unconditional logistic regression models were used to obtain maximum likelihood estimates of the ORs and their 95% confidence intervals (CIs), after adjusting for potential confounding variables. Risk factors previously identified as having an independent association with breast cancer were controlled in all models. These included age, personal history of fibroadenoma, age at first live birth, physical activity, waist-to-hip ratio, and daily meat intake. Age was included as a continuous variable throughout, and categorical variables were treated as indicator variables in the model. Quartile and tertile distributions of dietary intakes among controls were used to categorize all dietary intake variables. In the analyses including dietary factors, energy adjustment was performed using the standard multivariate method (22) . Tests for trend were performed by entering categorical variables as continuous. Stratified analyses were used to evaluate the potential modifying effect of age, menopausal status, and folate and folate cofactor intakes on breast cancer risk associated with MTHFR genotypes and of MTHFR genotypes on breast cancer risk associated with folate intake. Tests for multiplicative interaction were done by including multiplicative variables in the logistic model and performing the likelihood ratio test. All statistical tests were based on two-sided probabilities using SAS, Version 8.2 (SAS Institute, Inc., Cary, NC).
Results
Comparisons between cases and controls on select demographic factors, established risk factors, and dietary factors are presented in Table 1 . Cases were, in general, more highly educated, more likely to have a history of fibroadenoma, younger at menarche, older at first live birth and menopause, less likely to be physically active, and more likely to have a higher body mass index and waist-to-hip ratio than controls.
Cases also had higher average daily intakes of animal foods, methionine, and vitamin B 6 and lower average daily intake of folate than controls.
The frequencies of MTHFR alleles and genotypes by casecontrol status and the association between MTHFR genotypes and breast cancer risk are presented in Table 2 . The frequencies of the 677T and 1298C alleles were 0.41 and 0.18, respectively, among the controls. These were virtually identical to the frequency among the cases. Among the controls, the distributions of the MTHFR genotypes did not differ from the predicted distribution under Hardy-Weinberg equilibrium (P ϭ 0.44 for the C677T polymorphisms and P ϭ 0.58 for the A1298C polymorphisms). Risk of breast cancer did not differ statistically for the C677T or A1298C genotypes or for their combination. Similar associations were observed in analyses stratified by age and menopausal status (data not shown in table).
The joint association of MTHFR genotype and dietary folate intake with breast cancer risk is presented in Table 3 . Low intake of folate was associated with an increased risk of breast cancer among all genotypes, particularly subjects with the TT genotype (OR ϭ 2.51; 95% CI: 1.37-4.60) There was a significant multiplicative interaction between folate intake and C677T polymorphism in relation to breast cancer risk (P ϭ 0.05). Elevated ORs were observed to be associated with folate a The frequencies of the 677T allele were 41.4% in cases and 41.8% in controls (P ϭ 0.81) and the frequencies of the 1298C allele were 17.6% in cases and 17.5% in controls (P ϭ 0.95). b All ORs are adjusted for age, waist-to-hip ratio, age at first live birth, physical activity, menopausal status, and total meat intake. intake regardless of A1298C genotype, although the trend was statistically significant in only the AA group. To examine further the C677T association, analyses were restricted to 1298AA individuals because of a small sample size for the AC and CC genotypes. Again, low intake of folate was associated with increased risk for all genotypes, and the increased risk was greatest among those with 677TT genotype (OR ϭ 2.16, 95% CI: 1.09 -4.28, p for trend ϭ 0.002, p for interaction ϭ 0.06).
There was a suggestive reduced risk associated with the TT genotype among those with high folate intake, although the OR was not statistically significant. The joint associations of MTHFR C677T genotypes and folate intake with breast cancer risk are presented in Table 4 , after stratifying by folate cofactor intake. With the exception of the high vitamin B 6 stratum, low folate intake was associated with an elevated risk of breast cancer, and the association appeared stronger among subjects with the TT genotypes. None of the tests for multiplicative interactions, however, was statistically significant, perhaps because of a small sample size in these stratified analyses.
Discussion
We found in this case-control study that there was no statistically significant association between the risk of breast cancer and MTHFR C677T or A1298C genotypes. However, MTHFR C677T genotype was a statistically significant effect modifier of the association between folate intake and breast cancer risk. Among those with the 677TT genotype, low folate intake was associated with a more substantial increased risk than those with other genotypes. These are novel findings consistent with the possible role of MTHFR and folate in the etiology of cancer.
MTHFR polymorphisms have not been adequately investigated in relation to breast cancer risk. Only three previous small studies have examined MTHFR polymorphisms and breast cancer risk (16 -18) . In the first, a study among Jewish women, MTHFR C677T genotype was determined in 491 women with sporadic (n ϭ 355) or hereditary (n ϭ 136) breast and/or ovarian cancer and in 69 asymptomatic BRCA1/2 mutation carriers (16) . The prevalence of the T allele was not significantly different between sporadic cases and the asymptomatic carriers, women diagnosed at a young and older age, and BRCA1/2 carriers with and without cancer. The prevalence of the T allele was more frequent among women with bilateral breast cancer or with both breast and ovarian cancers than among women with only unilateral breast cancer. In the second study, a hospital-based, case-control study among postmenopausal Caucasian women (149 cases and 171 controls), it was reported that the MTHFR 677T (val) allele was more prevalent in cases than controls (17) , which is in contrast to the results from the third case-control study conducted in the United Kingdom (62 cases, 66 controls), the only previous study that reported risk of breast cancer associated with both the C677T and A1298C polymorphisms (18) . The British study reported breast cancer risk was reduced among those homozygous for the 677T allele (OR ϭ 0.39; 95% CI: 0.12-1.24) or 1298C allele (OR ϭ 0.24; 95% CI: 0.06 -0.97). However, no modifying effect of the MTHFR C677T genotype was noted on the association between folate intake and breast cancer risk. There was some evidence of a joint association of folate and the A1298C genotype, but the sample size was not large enough to examine this association.
We did not find an overall reduced risk of breast cancer associated with MTHFR 677TT or 1298CC genotypes, which is not consistent with the British study of breast cancer (17) and some of the previous studies for other cancers. Two of three case-control studies of colorectal cancer and the MTHFR C677T polymorphism observed an overall reduction in risk associated with the TT genotype (10, 11) , as did studies of oral cancer (23) and adult acute lymphocytic leukemia (24) . We also found a similar weak association among women with high intake of folate and folate cofactors. However, other studies of colorectal cancer (12) , colorectal adenoma (13, 14, 25) , gastric cancer (9), lung cancer (26) , and acute myeloid leukemia (24) found no association or an increased risk of cancer for individuals with the TT genotype. Our observation for a stronger inverse association of folate intake and breast cancer risk among women with the TT genotype is supported by the majority of studies examining a similar association for other cancers (10 -12, 14, 15, 23) , and is consistent with the role of folate in breast carcinogenesis. We, and others, have previously found a decreased risk of breast cancer among those with high intake level of folate (19, (27) (28) (29) (30) (31) (32) (33) . Low folate intake is associated with an increased misincorporation of uracil and chromosome breaks (34, 35) and aberrant DNA methylation (35, 36) . The critical factor in breast carcinogenesis may be an appropriate balance between the availability of for DNA methylation and 5,10-methylene-S-adenosylmethioninetetrahydrofolate for DNA synthesis. It is plausible that individuals with the 677TT genotype are particularly susceptible to the carcinogenic consequences of folate insufficiency. This genotype, in the presence of low folate, is associated with higher levels of homocysteine, lower levels of methylated folates and, therefore, reductions in genomic DNA methylation (37, 38) . Our finding for a positive association of C677T genotype with low folate intake (OR ϭ 2.51, 95% CI: 1.37-4.60) appears to support this notion. Conversely, in folate-replete conditions, the availability of 5,10-methylenetetrahydrofolate for nucleotide synthesis may be adequate or increased for these individuals because of the genetically determined decreased activity of MTHFR. This could explain the lower risk of this genotype among those with high folate levels in this (OR ϭ 0.70, 95% CI: 0.40 -1.23 for 677TT) and other studies (10, 12, 14, 15) . Therefore, the effect of MTHFR on breast cancer risk in a particular population may depend on the intake level of folate in that population. With increased folic acid fortification in the United States population, the general intake of folate may be higher than that from the Chinese, whose folate intake is primarily obtained from unfortified diets. This may explain, in part, the overall absence of association of MTHFR genotype with breast cancer risk in our study. The relationship between folate metabolism and carcinogenesis is likely to be a complex biological sum of genetic and nutritional differences. In our study, the association of folate and breast cancer risk was similar for all genotypes when intakes of vitamin B 12 , B 6 , or methionine were low. Vitamin B 12 , vitamin B 6 , and methionine all have important roles in one-carbon metabolism; vitamin B 12 is a cofactor for the transfer of the methyl group from folate to methionine, vitamin B 6 is a coenzyme for the formation of 5,10-methylene-5,10-methylenetetrahydrofolate and the catabolism of homocysteine, and methionine is the precursor for S-adenosylmethionine. It is possible that below a certain intake threshold of vitamin B 12 and methionine, the effect of MTHFR C677T genotype or folate intake is reduced or negated and that once this threshold is surpassed, both folate and MTHFR genotype have a greater impact on breast cancer risk. The inverse association with breast cancer risk among those with a high vitamin B 6 intake was unexpected and cannot be readily explained by the above rationale. This finding needs to be re-evaluated in future studies.
As with any case-control study, the potential for selection and recall biases must be considered. However, selection bias is unlikely to be a major issue in this study; both cases (91%) and controls (90%) had very high participation rates. Not only did this study have a high participation rate, it also had a high blood collection rate (Ͼ80%). Although it is possible that cases and controls may have had differentially recalled intakes of foods that contributed to the nutrients in this study, fruit and vegetable intake, the major contributors to folate, methionine, and vitamin B 6 intakes, did not significantly differ between cases and controls. Approximately 50% of cases were interviewed within 15 days of diagnosis and the majority (80%) were interviewed within 4 months, thus reducing potential recall bias attributable to dietary change related to a diagnosis of cancer. In addition, recall of diet would unlikely be related to MTHFR genotype and, therefore, could not account for the associations we observed in this study. Additionally, misclassification in the assessment of folate intake may have occurred from using the Unites States Department of Agriculture food composition database. However, any such misclassification would be nondifferential between cases and controls and would usually result in a bias toward the null. Confounding by other factors is always a concern in epidemiological studies. We observed little confounding when we carefully adjusted for known risk factors. Although it is possible that residual confounding may still exist, for example, from dietary factors not considered in this study, additional factors are not likely to explain the strength of the observed associations. Other strengths of our study include the population-based design, the estimation of folate intake in a population of nonusers of alcohol and vitamin supplements, and the large sample size that facilitated examination of modifying effects.
In summary, we found that, although there was no overall relationship between MTHFR genotype and breast cancer risk, women with low intake of folate and who are homozygous for the MTHFR 677T polymorphism may be at substantially increased risk for breast cancer. Our data also suggest this association may be further modified by vitamin B 12 , vitamin B 6 , and methionine intake. This study adds support to the literature that one-carbon metabolism and MTHFR polymorphisms have a role in carcinogenesis and may be important in breast carcinogenesis. 
Introduction
Methylenetetrahydrofolate is an important enzyme in folate metabolism. It irreversibly converts 5,10-methylene tetrahydrofolate (THF) to 5-methyl THF which provides the methyl group for the de novo synthesis of methionine synthase and DNA methylation [1] . It also helps determine the folate levels available for DNA synthesis and repair [2] . Two common polymorphisms in the MTHFR gene have been identified [3, 4] . The 677C fiT polymorphism codes for an alanine to valine substitution in the N-terminal catalytic domain and results in an allozyme with approximately 65 and 30% of the activity of the wild-type protein for heterozygotes and homozygotes, respectively [3] . Allele frequencies for the 677T variant range approximately from 0.24 to 0.44 in European and Caucasian populations, 0.06 in an African population, and 0.35 to 0.41 in Asian populations [5, 6] . The AfiC polymorphism at nucleotide 1298 codes for an alanine to glutamine substitution in the C-terminal regulatory domain [4] . Individuals homozygous for the 1298C allele have approximately the same enzyme activity as those heterozygous for the 677T allele [4, 7] . Reported frequencies for the 1298C allele are 0.22-0.36 in Europe, 0.18-0.36 in North America, and 0.17-0.19 in Asia [8] .
Adjuvant chemotherapy greatly improves relapsefree and overall survival of breast cancer patients [9] [10] [11] . A classical treatment regime for metastatic disease is a combination of cyclophosphamide, methotrexate (MTX), and fluorouracil (5FU) (CMF). Both MTX and 5FU exert their anti-neoplastic activities through folatepathway inhibition. It has been reported that the MTHFR 677TT genotype is associated with increased toxicity of MTX and increased clinical response to 5FU in treatment of leukemia, and cancers of the breast, ovary, and colorectum [12] [13] [14] [15] . The relationship between MTHFR genotypes and survival from breast cancer has not been previously investigated. In this study, we examine this association among a cohort of Chinese breast cancer patients who had participated in the Shanghai Breast Cancer Study and had received adjuvant chemotherapy as part of their treatment for breast cancer. 
Materials and methods
Participants and data collection
The Shanghai Breast Cancer Study is a populationbased case-control study that recruited breast cancer patients during August 1996 through March 1998 in Shanghai, China. Over 98% of people living in Shanghai are Han Chinese. Eligible cases were residents of urban Shanghai aged 25-64 years with a newly diagnosed breast cancer who had no prior history of cancer. Cases were identified through a rapid case-ascertainment system supplemented by the population-based Shanghai Tumor Registry. A total of 1602 cases were found to be eligible for the study, and, of these, 1459 (91.1%) completed in person interviews, 17 (1.1%) were deceased before interview, 109 (6.8%) refused to participate and 17 (1.1%) could not be located. Information on cancer diagnosis, disease stage (TNM), estrogen receptor (ER)/ progesterone receptor (PR) status, and treatment were abstracted from medical records at the patient's hospital. Chemotherapy regimen information was not collected in the study. Blood samples were available for 1193 women (81.8%). These samples were processed within 6 h of collection and stored at )70°C. For nearly 50% of the cases, blood sample collection and in-person interviews were completed before any cancer therapy. During March 2000 to January 2003, the 1459 participating cases were followed up to collect data on disease progression, recurrence, survival status, cause of death, and quality of life among survivors. In-person (n ¼ 1241, 85.0%) or telephone interviews (n ¼ 49, 3.4%) were completed by the patient or by next of kin for deceased patients (n ¼ 197). The survival status of the remaining 169 cases was established by linkage to the vital statistics registry at the Shanghai Center for Disease Control and Prevention (SCDCP). Four cases did not have sufficient information for linkage and were excluded from the study. Through the linkage, 43 deaths were identified and information on dates and causes of death were obtained. To allow a delay in the transmittal of death information to the SCDCP, we assigned December 30, 2002 as the date of last contact to the cases (n ¼ 122) whose files were not found in the vital statistics registry. This study was approved by the Institutional Review Board of Vanderbilt University and all of the participating institutions; informed consent was obtained for all study participants.
Laboratory methods
Genomic DNA was extracted from blood samples with the Puregene Ò DNA isolation Kit (Gentra Systems, Minneapolis, MN) following the manufacturer's protocol. Genotyping for the MTHFR C677T and A1298C polymorphisms were performed using PCR-RFLP methods described elsewhere [16] . Briefly, the primers for C677T analysis were: 5 0 -TGAAGGAGAAGGTGT CTGCGGGA-3 0 (exonic) and 5 0 -AGGACGGTGC GGTGAGAGTG-3 0 (intronic). The primers for A1298C analysis were: 5 0 -GGGAGGAGCTGACCAGTGCAG-3 0 and 5 0 -GGGGTCAGGCCAGGGGCAG-3 0 . The PCR reactions were performed in a Biometra Ò TGradient Thermocycler. Each 20 ml of PCR mixture contained 10 ng DNA, 1· PCR buffer (50 mM KCl, 10 mM TrisHCl, pH 9.0), 1.5 mM MgCl 2 , 0.2 mM each of dNTP, 0.5 mM of each primer, and 1 unit of Taq DNA polymerase. The reaction mixture was initially denatured at 94°C for 3 min. For C677T polymorphisms, PCR was performed in 30 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 45 s. For A1298C polymorphisms, PCR was performed in 35 cycles of 94°C for 45 s, 65°C for 45 s, and 72°C for 45 s. The PCR was completed by a final extension cycle at 72°C for 7 min.
For C677T polymorphisms, each PCR product (10 ll) was digested with 10 units of Hinf I at 37°C for 3 h. The DNA fragments were then separated using 3% agarose gel and detected by ethidium bromide staining. The CfiT substitution at nucleotide 667 creates a Hinf I digestion site. The PCR product (198 bp) with T allele was digested to 2 fragments (175 and 23 bp), whereas the PCR product with wild type C allele cannot be cut by Hinf I. For A1298C polymorphisms, each PCR product (10 ll) was digested with 5 units of Fnu4H I at 37°C for 3 h followed by 3% agarose gel electrophoresis and ethidium bromide staining. The AfiC substitution at nucleotide 1298 creates a Fnu4H I site. The PCR product (138 bp) with C allele was digested to 2 fragments (119 and 19 bp), whereas the PCR product with wild type A allele cannot be cut by Fnu4H I.
Quality control (QC) samples were included in various batches of samples assayed for the polymorphisms. The consistency rate was 98.5% in 119 QC samples that were repeated in the genotyping assays with their identities unknown to lab staff. Excluding a few participants for whom sufficient DNA was not available or for whom the genotyping assay failed, genotyping data were obtained from 1038 to 1045 participants for C677T and A1298C polymorphisms, respectively.
Data analysis
All analyses were restricted to the 1366 (93.6%) who were known to have received both surgery and chemotherapy as part of their treatment for breast cancer. MTHFR analyses were further restricted to the women who had genotyping data. Overall survival time was calculated as the time from diagnosis to death from any cause and censored at date of last contact. KaplanMeier survival method was used to calculate the 1, 3, and 5-year survival rates and the Log Rank Test was applied to test the differences in survival across different genotypes. Cox proportional hazards model was used to estimate hazard ratios (HR) and their 95% confidence intervals (CI) after adjusting for use of radiotherapy and Tamoxifen and known prognostic factors including TNM stage and age. Age was included as a continuous variable throughout, and categorical variables were treated as indicator variables in the model. Stratified analyses were used to evaluate the potential modifying effect of age, ER/PR status, and TNM stage on risk associated with MTHFR genotypes. Tests for multiplicative interaction were done by including multiplicative variables in the logistic model and performing the likelihood ratio test. All statistical tests were based on twosided probabilities using SAS, version 8.2 (SAS Institute, Inc., Cary, NC).
Results
Characteristics of participants and overall 5-year survival rates by characteristic are presented in Table 1 for the entire cohort and for the subset with MTHFR data. Distributions and 5-year survival rates were consistent between both groups. Of those with known ER and PR status, most were positive for ER or PR. Overall 5-year survival was 84.63%. Survival was somewhat lower for those who were older at diagnosis. The majority of patients received radiotherapy (66.2%) or took Tamoxifen (70.1%) (data not shown in table).
In Table 2 , the frequencies of MTHFR alleles and genotypes are presented among all the study participants and by TNM stage and ER/PR status. The frequencies of the 677T and 1298C alleles were 0.41 and 0.18 respectively. Neither the C677T nor the A1298C genotypes were significantly associated with the stage at diagnosis or ER/ PR status. The distribution of A1298C genotypes was similar overall and across TNM stage and ER/PR status. Disease stage and ER/PR status also did not appear to be influenced by the combined genotype of C677T and A1298C. No significant differences in genotype distribution were observed. The distributions of the MTHFR genotypes did not differ from the predicted distribution under Hardy-Weinberg equilibrium ( p ¼ 0.83 for C677T and p ¼ 0.07 for A1298C polymorphisms).
In Table 3 ) . MTHFR C667T results for stage III were similar to the combined analysis of stages III and IV (data not shown in table). There was no evidence of a survival difference by the presence of the 1298C allele. Sample sizes did not permit separate analysis of the A1298C genotypes or stage IV breast cancer alone.
Discussion
In this population-based breast cancer cohort study, we found that MTHFR genotypes were not associated with overall survival in the entire cohort. However, the 677TT genotype was associated with poorer long-term survival among those with late stage disease. This is the first report suggesting that MTHFR genotype affects survival from breast cancer. MTHFR has a critical role in folate metabolism. Decreased activity of MTHFR increases the folate pool available for DNA synthesis and cell proliferation. The MTHFR 677T polymorphism results in an allozyme with lower activity; it is approximately 70% reduced in vitro for homozygotes [3] . Folate pathway inhibitors such as MTX and 5-FU are important chemotherapeutic drugs used in the treatment of breast cancer. The primary target of MTX is dihydrofolate reductase and, thus, MTX increases the intracellular pool of dihydrofolate, an inhibitor of MTHFR [17] while simultaneously functioning as an anti-folate and a thymidylate synthase (TS) inhibitor [18] . 5FU, another common drug for treatment of breast cancer and TS inhibitor, must form a ternary complex with TS and 5,10-methylene THF [19] . Situations in which the availability of 5,10-methylene THF is increased, including decreased activity of MTHFR, will result in a more stable complex and maximal inhibition of TS, thus decreasing proliferation and increasing cytotoxicity. This is supported by the report of greater chemosensitivity of cells with 677 TT MTHFR [20] and the greater response to 5FU of metastatic colorectal cancer patients with 677TT genotype [15] . Recently, Sohn et al. [20] transfected the breast cancer cell line MDA-MB-435 with 677CC or 677TT human MTHFR cDNA to examine chemosensitivity to MTX and 5-FU, as measured by the percentage of cell survival. As expected, cells expressing the 677T MTHFR had 35% lower MTHFR activity, and proportionally less methyl THF, more formyl THF, more methylene THF, and grew more rapidly than the cells expressing the C677 MTHFR. However, the cells with 677T MTHFR were more chemosensitive to 5FU but less chemosensitive to MTX treatment. Although we do not have specific chemotherapy information for each patient in this study, based on data collected from a recent survey in Shanghai, over 84% of breast cancer patients received 5FU and 39% MTX. Therefore, we would expect that in the study population, patients who carry the 677TT genotype would be more sensitive to chemotherapy, in general, and more likely to have better survival, if the chemotherapy dose is appropriate. This hypothesis has been supported by one study conducted in colon cancer patients who received 5FU [15] , although there was no association between survival from colon cancer and the 677T allele in another smaller study [21] . In our study, only women with the TT genotype and who had survived at least 2 years after an initial diagnosis of early stage disease had a possible increased survival, perhaps reflecting a better response to chemotherapy for those with localized disease. Contrary to the above hypothesis, we found that women with late-stage disease and the TT genotype had poorer survival, particularly in the later years of follow-up, possibly due to the chronic toxic effects of chemotherapy. In one report of 6 breast cancer patients who received cyclophophamide, MTX, and 5FU and experienced grade IV toxicity, 5 had the 677TT genotype [22] . Increased acute MTX toxicity has also been reported for TT carriers with ovarian cancer [14] , CML and bone marrow transplant [23] , acute leukemia [12] , and rheumatoid arthritis [24] . In a FrenchCanadian study of 201 children with acute lymphoblastic leukemia, the presence of the 677T allele was associated with a higher probability of relapse or death [25] . Survival was even poorer if the individuals had both the 677T allele and were homozygous for the triple repeat of the 5 0 UTR thymidylate synthase polymorphism, which is associated with increased TS levels.
Although we knew that all women in this study received chemotherapy as part of their treatment for breast cancer, specific chemotherapy data were not available. Because the type of chemotherapy prescribed is unlikely to be related to MTHFR genotype, confounding effect is not a concern for the study. However, if the survival differences associated with MTHFR genotypes are modified by chemotherapy type, the lack of this type of data in our population could have affected our results. In an on-going study of breast cancer survival in Shanghai, a similar sample of 341 women were recruited during 2003. Over 84% of patients received 5FU and 39% received MTX as part of their therapy. Specific regimens were as follows: CMF 32%, 31% cyclophosphamide, epirubicin and 5FU (CEF or FEC), and 1% doxorubicin and cyclophosphamide (AC). Because stage of disease (local vs. distant) is one of the most important factors that determines the type of therapy received, we examined the effect of genotype within stage. The results of this study suggest that there might be an interaction between MTHFR genotype and chemotherapy, and this hypothesis will need to be tested in future studies with both genotype and specific treatment information. Selection and survival biases were minimized by the population-based design, high participation rate of the identified cases, and high follow-up rate. Likewise there was also a high participation rate for DNA samples and participation was not likely affected by genotype. We also cannot exclude chance as a reason for our findings.
In summary, we found that the MTHFR 677TT genotype was associated with poorer long-term survival for women with late-stage breast cancer, but did not significantly affect survival from early-stage disease. We 
Introduction
Methionine, the precursor for the universal methyl donor, S-adenosylmethionine, is produced through the irreversible transfer of a methyl group from 5-methyltetrahydrofolate. This reaction is regulated by two enzymes, methionine synthase (MTR) and methionine synthase reductase (MTRR). MTR is polymorphic at nucleotide 2,756 (A-to-G) and has been associated with decreased plasma homocysteine levels (1-3).
MTRR is polymorphic at nucleotide 66 (A-to-G) and the variant has a lower affinity for MTR (4) and is inconsistently associated with homocysteine level (5-7), although it is a risk factor for neural tube defects (8) and Down syndrome (9) in conditions of higher homocysteine. There is no report on either MTR or MTRR in relation to breast cancer risk. In an extension of our previous reports that folate intake was inversely associated with breast cancer risk (10) and that this association was particularly strong among women with the methylenetetrahydrofolate reductase (MTHFR) 677TT genotype (11), we investigated whether these associations may be modified by MTR and MTRR genotypes.
Materials and Methods
The Shanghai Breast Cancer Study is a large population-based case-control study conducted in urban Shanghai, China. Detailed study methods have been published previously (12) . In brief, cases ages between 25 and 64 years were identified through a rapid case-ascertainment system supplemented by the population-based Shanghai Cancer Registry. Controls were identified from the Shanghai Resident Registry and frequency matched to the expected age distribution of cases by 5-year age groups. All subjects completed an in-person interview. Dietary intakes were assessed using a 76-item food frequency questionnaire that captured >85% of food intake in Shanghai (13) . Blood samples were collected from 1,193 (82%) cases and 1,310 (84%) controls and used in this study for genotyping assays. MTRR Ile   22 Met (A66G, rs1801394) genotyping was done using the Taqman 5V-Nuclease Assay (C_3068176_10; Applied Biosystems, Foster City, CA). MTR Asp 919 Gly (A2756G, rs1805087) genotyping was done by BioServe Biotechnologies Ltd. (Laurel, MD) using Masscode assay (14) . The consistency rate of quality control samples was 100% for MTR A2756G and 96% for MTRR A66G. All dietary intake analyses only included cases (92.1%) and controls (91.3%) who did not use alcohol regularly or take vitamin supplements. Unconditional logistic regression models were used to calculate odds ratios (OR) and their 95% confidence intervals (95% CI) after adjusting for potential confounding variables. Diet was categorized into tertiles based on the control distribution. Energy was adjusted using the standard multivariate method (15) . Stratified analyses were used to evaluate the potential modifying effect of MTHFR genotypes and folate and folate cofactor intakes.
Results
The frequencies of the MTR A2756G and MTRR A66G alleles were 0.10 and 0.24, respectively, among the controls who were not statistically different from the cases (data not shown). The genotype distributions among both cases and controls did not differ from the predicted distribution under Hardy-Weinberg equilibrium. Risk of breast cancer did not differ statistically by the MTR or MTRR genotypes either overall or by menopausal status nor did the genotypes modify the null association with MTHFR C677T genotype (Table 1) . Likewise, there were no clear differences in risk for breast cancer and the joint MTHFR-MTR-MTRR genotypes.
The joint associations of MTR and MTRR genotypes and dietary folate and folate cofactor intake with breast cancer risk are presented in Table 2 . Low intake of folate was associated with an increased risk among all genotypes, and the strength of the association did not differ by genotype. Risk associated with the genotypes was not statistically significantly different than one within all strata of methionine, vitamin B 12 , and vitamin B 6 intakes.
Discussion
We found that there was no statistically significant association between the risk for breast cancer and MTR A2756G or MTRR A66G genotypes. We further found that this association was not modified by MTHFR C677T genotypes or intakes of folate, methionine, vitamin B 12 , or vitamin B 6 . This is the first report of MTR and MTRR genotypes in relation to breast cancer risk. MTR has been associated with a reduced risk for both colorectal cancer (16, 17) and acute lymphoblastic leukemia (18) and increased risk for malignant lymphoma (19) and not associated with cancer risk for non-Hodgkin's lymphoma (18, 20) and uterine cancer (21) . In the only two studies that have evaluated the MTRR A66G genotype in relation to cancer risk, there was no observed association with acute lymphoblastic leukemia, non-Hodgkin's lymphoma, or gastric cardia cancer (20, 22) , although there was an increased esophageal cancer risk among those who did not consume alcohol (22) .
MTR and MTRR are critical enzymes responsible for the biosynthesis of methionine, the precursor for methylation reactions, and the regeneration of tetrahydrofolate for nucleotide biosynthesis. Under conditions of adequate methionine, f40% of homocysteine is remethylated to methionine through the activity of these enzymes (23) . Alterations, therefore, in the function of these enzymes could have important effects on DNA methylation, synthesis, and repair. The MTRR A66G variant has a 3-to 4-fold lower affinity for MTR (4) and has been associated with altered blood or plasma levels of homocysteine, folate, or vitamin B 12 in some but not all studies (5-7, 24, 25) . Likewise, reports of MTR A2756G and homocysteine are conflicting (7, 26) . We did not find any statistically significant associations between these genotypes and breast cancer risk even among conditions of replete and low intake. Nor did we observe any associations when the lowactivity MTHFR, the rate-limiting enzyme for the methionine cycle, was either present or absent. If these particular variants of these critical enzymes do indeed have important functional consequences, our data suggested that these consequences do not seem likely to alter one-carbon metabolism sufficiently to affect risk for breast cancer. This case-control study is one of the largest and most comprehensive evaluations of genetic variants in enzymes involved in the remethylation of homocysteine. Potential biases are limited in this study because both cases and controls had very high participation rates (>90%) and high blood donation rates (>80%). Fruit and vegetable intake, the major contributors to folate, methionine, and vitamin B 6 intakes, did not significantly differ between cases and controls, and recall of diet would unlikely be related to genotype. We also observed little confounding when we carefully adjusted for known risk factors and any possible residual confounders would need to be very strong to alter the null associations observed in this study. We cannot exclude the possibility that these genotypes may be related to risk of breast cancer in an older population; however, the null association was not modified by menopausal status. Particular strengths of our study include the population-based design, the estimation of folate and cofactor intake in a population of nonusers of alcohol and vitamin supplements, and the large sample size that facilitated examination of modifying effects.
In summary, we found that MTR and MTRR genotypes are not likely to play an important independent role in breast cancer etiology. This is the first evaluation of these genotypes with breast cancer risk and future studies are warranted in populations with different nutrient intake.
